The Center for Molecular Immunology is a Cuban biotechnology institute dedicated to the production of monoclonal, therapeutic and radioactive antibodies, from the culture of cells.
The Center of Molecular Immunology known by the acronym CIM is a Cuban biotechnology institute that is part of the first Scientific Pole of the West of Havana, Capital of the Island of Cuba. It was inaugurated in 1994 and is dedicated to the production of monoclonal antibodies (mAbs), therapeutic and radioactive, as well as other functions. Center for Molecular Immunology of Cuba
In the Center of Molecular Immunology cancer immunotherapy is investigated, recombinant erythroproyectin is produced, therapeutic vaccines, products for radioimmuno therapy and diagnostic radioimmuno are obtained. It is dedicated to basic research, manufacturing and product development from the cultivation of superior cells.
Designed with international construction standards, modern equipment and a human capital of recognized scientific and professional prestige, in its more than 20 years of outstanding trajectory the Molecular Immunology Center has obtained important recognitions among which are:
By obtaining a chimeric and humanized antibody against the epidermal growth factor receptor, for its diagnostic and therapeutic use, it obtained a Gold Medal and an award from the World Intellectual Property Organization for the acM hR3 patent.
The investment referred to the Therapeutic Vaccine for the treatment of advanced lung cancer, won the Prize of the World Intellectual Property Organization in 2008.
This scientific institution has dedicated itself to producing new biopharmaceuticals destined to chronic noncommunicable diseases and to cancer, conducting clinical trials in Cuba and other countries of the world with advice from Cuban personnel, contributing in a sustained way to the productive economic development of the nation.
Therapeutic vaccines developed with monoclonal antibodies by the Center of Molecular Immunology of Cuba
Vaccines Vaxira and CIMAvax for Lung Cancer
Vaccine CIMAher for Head and Neck Cancer
Medical Services Providers
